Is Meta Materials A Good Stock To Buy Right Now?

This past meme stock has a non-invasive glucose monitoring game changer in its pipeline, but is Meta Materials a good investment right now?
Oct. 7, 2021
Unlock Free Stock Insights + 50% Off Discount Code!
Join thousands of savvy investors and get:
  • Weekly Stock Picks: Handpicked from 60,000 global options.
  • Ten Must-Have Stocks: Essential picks to hold until 2034.
  • Exclusive Stock Library: In-depth analysis of 60 top stocks.
  • Proven Success: 10-year track record of outperforming the market.
Sign up to our mailing list now and enjoy a 50% discount on premium services!
By submitting your email address, you consent to us keeping you informed about updates to our website and about other products and services that we think might interest you. You can unsubscribe at any time. Please read our Privacy Policy and Terms of Use.

Meta Materials (NASDAQ: MMAT), the first metamaterials company to be listed on the NASDAQ exchange, had recently exited meme-stock status after a massive sell-off left the company nearly 75% off its peak. The company is responsible for developing and manufacturing new materials and nanocomposites with applications in the defense, electronics, medical, automotive, and aerospace sectors. One product currently in development is glucoWISE(r), a non-invasive tool for measuring blood sugar without drawing blood. Disrupting the diabetes market can be a very lucrative endeavor, so is Meta Materials a good investment for me to buy?

The bull case for Meta Materials

According to the company's Q2 2021 report, revenue and gross profit are both up nearly 200% year-over-year (YoY). With over 60 patents worldwide, Meta Materials' strength lays in its innovation and R&D in developing commercially viable products. One such product is glucoWISE(r) (currently in development) which will allow users to discreetly and effortlessly test their blood sugar without breaking the skin and wirelessly send the data to their smartphone; there it can be analyzed for historical data and future forecasts.

This offering is unlike anything currently available on the market and will likely replace current testing strips. The blood glucose monitoring market is projected to grow 68% to be worth nearly $20 billion by 2028 and a non-invasive, more hygienic, and fully digitized product is just what the doctor ordered for the growing diabetes market.  This device, along with its range of holographic, augmented reality (AR), and glare protection products are perhaps the reason why Meta Materials was the recipient of the Lux Innovator of the Year Award this year.

The bear case for Meta Materials

Meta Materials expected to start taking pre-orders for glucoWISE(r) three years ago. That is yet to happen; in fact, the company hasn't even started clinical trials for the device. As for the numbers, the company has increased its net loss by over 185% and its loss per share has grown by over 60%, YoY. The company also completed a reverse 2-for-1 stock split which is often undertaken to increase share price in order to avoid delisting. 

So, is Meta Materials a good investment?

It may be cheap at around $5, but the stock is still overvalued. Aside from this point, I would advise against taking a position until at least two earnings reports are published, as per our policy here at MyWallSt. 

Quickfire round:

1. When did Meta Materials go public?

June 28, 2021 via a reverse SPAC merger with Torchlight Energy Resources

2. Who is the CEO of Meta Materials and where is its headquarters?

Co-founder and President Dr. George Palikaras; Dartmouth, Canada

3. Meta Materials?

From the Greek 'meta' meaning beyond

Find more growth opportunities by subscribing to MyWallSt today and checking out our shortlist of market-beating stocks. Click here to start your free access so you can get on the path to financial freedom


Unlock Free Stock Insights +50% Off Discount Code!
Join thousands of savvy investors and get:
  • Weekly Stock Picks: Handpicked from 60,000 global options.
  • Ten Must-Have Stocks: Essential picks to hold until 2034.
  • Exclusive Stock Library: In-depth analysis of 60 top stocks.
  • Proven Success: 10-year track record of outperforming the market.
Sign up to our mailing list now and enjoy a 50% discount on premium services!
By submitting your email address, you consent to us keeping you informed about updates to our website and about other products and services that we think might interest you. You can unsubscribe at any time. Please read our Privacy Policy and Terms of Use.

The Home of Successful Investing.

© 2024 MyWallSt Ltd. All rights reserved.


Services

Content

Social

Company

Support

Resources


This website is operated by MyWallSt Ltd (“MyWallSt”). MyWallSt is a publisher and a technology platform, not a registered broker-dealer or registered investment adviser, and does not provide investment advice. All information provided by MyWallSt Limited is of a general nature for information and education purposes, and you should not construe any such information as investment advice. MyWallSt Limited does not take your specific needs, investment objectives or financial situation into consideration, and any investments mentioned may not be suitable for you. You should always carry out your own independent verification of facts and data before making any investment decisions, as we cannot guarantee the accuracy or completeness of any information we publish and any opinions that we publish may be wrong and may change at any time without notice. If you are unsure of any investment decision you should seek a professional financial advisor. MyWallSt Limited is not a registered investment adviser and we do not provide regulated investment advice or recommendations. MyWallSt Limited is not regulated by the Central Bank of Ireland. MyWallSt Limited may provide hyperlinks to web sites operated by third parties. Your use of third party web sites and content, including without limitation, your use of any information, data, advertising, products, or other materials on or available through such web sites, is at your own risk and is subject to the third parties' terms of use.